ArticleEuropean heart journal open2022

Time to initiation of lipid-lowering drugs for subclinical atherosclerosis: sub-study of VIPVIZA randomized controlled trial, with single-arm cross-over.

Henrik Holmberg et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.